Retrospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2022; 28(20): 2214-2226
Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2214
Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral
Xiao-He Li, Rui Huang, Ming Yang, Jian Wang, Ying-Hui Gao, Qian Jin, Dan-Li Ma, Lai Wei, Hui-Ying Rao
Xiao-He Li, Rui Huang, Ming Yang, Jian Wang, Ying-Hui Gao, Qian Jin, Dan-Li Ma, Lai Wei, Hui-Ying Rao, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People’s Hospital, Beijing 100044, China
Ming Yang, Lai Wei, Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 100044, China
Author contributions: Li XH, Rao HY and Wei L designed the protocol of this study; Li XH, Huang R, Yang M, Wang J, Gao YH, Jin Q and Ma DL collected the data; Li XH analyzed and interpreted the patient data and was major contributors in writing the manuscript; Wei L and Rao HY give advice in study design, statistical analysis and writing the manuscript; All authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81870406; and Nature Science Foundation of Beijing Municipality, No. 7182174.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Peking University People’s Hospital (2020PHB039-01), and the requirement for patient informed consent was waived.
Informed consent statement: Patients were not required to provide informed consent for this study, as the analysis used anonymous clinical data. The Institutional Review Board of Peking University People’s Hospital approved waiving the requirement for patient informed consent.
Conflict-of-interest statement: Prof. Rao reports grants from National Natural Science Foundation of China (NSFC), No. 81870406, and Beijing Natural Science Foundation, No. 7182174 during the conduct of the study.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Ying Rao, MD, Chief Doctor, Professor, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People’s Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing 100044, China. rao.huiying@163.com
Received: September 30, 2021
Peer-review started: September 30, 2021
First decision: March 11, 2022
Revised: March 25, 2022
Accepted: April 21, 2022
Article in press: April 21, 2022
Published online: May 28, 2022
Processing time: 239 Days and 3.3 Hours
Core Tip

Core Tip: In this prospective, comparative study, the correlation between the contrast enhancement index (CEI) in the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid enhanced magnetic resonance imaging and liver pathology measures was analyzed in patients with chronic hepatitis C. It was determined that the CEI has good diagnostic performance and is more useful than serological markers and transient elastography for hepatic-fibrosis monitoring in patients achieving sustained virological response.